TGTX Interest Income from 2010 to 2026

TGTX Stock

USD 27.76 1.36 4.67%

TG Therapeutics Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income is likely to outpace its year average in 2026. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2010-12-31

Previous Quarter

6.1 M

Current Value

6.4 M

Quarterly Volatility

2.7 M

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 338.1 K, Interest Expense of 29 M or Total Revenue of 397.3 M, as well as many indicators such as Price To Sales Ratio of 11.37, Dividend Yield of 4.0E-4 or PTB Ratio of 18.59. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.

Build AI portfolio with TGTX Stock

Check out the analysis of TG Therapeutics Correlation against competitors.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

The evolution of Interest Income for TG Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how TG Therapeutics compares to historical norms and industry peers.

Latest TG Therapeutics' Interest Income Growth Pattern

Below is the plot of the Interest Income of TG Therapeutics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. TG Therapeutics' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

TGTX Interest Income Regression Statistics

	Arithmetic Mean	2,767,578
	Geometric Mean	1,148,991
	Coefficient Of Variation	97.49
	Mean Deviation	2,593,585
	Median	857,000
	Standard Deviation	2,698,063
	Sample Variance	7.3T
	Range	6.2M
	R-Value	0.90
	Mean Square Error	1.5T
	R-Squared	0.81
	Slope	480,598
	Total Sum of Squares	116.5T

TGTX Interest Income History

	2026	6.4 M
	2025	6.1 M
	2019	5.3 M
	2018	857 K
	2017	294.5 K
	2016	323 K

Other Fundumenentals of TG Therapeutics

Net Interest Income

TG Therapeutics Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Common Stock	Property Plant Equipment	Short Term Debt	Short Term Investments	Long Term Debt	Current Deferred Revenue	Intangible Assets	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.88	-0.15	-0.8	0.87	1.0	0.79	0.88	0.0	0.66	0.47	0.85	0.82	0.24	-0.34	0.54	0.59	0.69	0.9	-0.5	-0.39	-0.15	0.45	0.98	0.98	0.89
Total Stockholder Equity	0.88		-0.58	-0.6	0.56	0.87	0.45	0.63	-0.04	0.65	0.79	0.55	0.46	0.02	-0.31	0.85	0.44	0.37	0.73	-0.37	-0.38	-0.02	0.78	0.89	0.87	0.7
Net Debt	-0.15	-0.58		0.0	0.31	-0.14	0.45	0.05	0.08	-0.38	-0.86	0.32	0.42	0.14	0.12	-0.89	0.04	0.34	-0.09	-0.05	0.18	-0.2	-0.85	-0.18	-0.13	-0.02
Retained Earnings	-0.8	-0.6	0.0		-0.75	-0.79	-0.61	-0.91	-0.01	-0.74	-0.21	-0.8	-0.73	-0.23	0.39	-0.33	-0.52	-0.88	-0.97	0.53	0.48	0.06	-0.19	-0.73	-0.73	-0.95
Total Liab	0.87	0.56	0.31	-0.75		0.87	0.95	0.88	-0.07	0.46	0.01	0.93	0.97	0.36	-0.36	0.11	0.66	0.84	0.81	-0.42	-0.41	-0.15	0.0	0.82	0.84	0.8
Total Current Assets	1.0	0.87	-0.14	-0.79	0.87		0.81	0.87	0.0	0.65	0.47	0.85	0.83	0.24	-0.33	0.52	0.58	0.68	0.89	-0.49	-0.38	-0.18	0.46	0.99	0.99	0.88
Net Receivables	0.79	0.45	0.45	-0.61	0.95	0.81		0.76	0.06	0.3	-0.07	0.92	0.98	0.28	-0.18	-0.06	0.52	0.73	0.67	-0.43	-0.18	-0.31	-0.07	0.78	0.81	0.71
Accounts Payable	0.88	0.63	0.05	-0.91	0.88	0.87	0.76		-0.06	0.76	0.17	0.84	0.85	0.32	-0.42	0.31	0.65	0.87	0.94	-0.37	-0.51	-0.15	0.15	0.8	0.81	0.88
Common Stock	0.0	-0.04	0.08	-0.01	-0.07	0.0	0.06	-0.06		0.14	0.04	-0.01	0.06	-0.03	0.87	-0.07	-0.67	-0.07	-0.01	-0.67	0.7	-0.11	0.02	0.07	0.07	0.1
Property Plant Equipment	0.66	0.65	-0.38	-0.74	0.46	0.65	0.3	0.76	0.14		0.42	0.43	0.41	0.17	-0.16	0.6	0.34	0.58	0.77	-0.33	-0.4	-0.01	0.39	0.63	0.6	0.68
Short Term Debt	0.47	0.79	-0.86	-0.21	0.01	0.47	-0.07	0.17	0.04	0.42		0.08	-0.07	-0.06	-0.1	0.88	0.06	-0.17	0.33	-0.21	-0.13	-0.15	1.0	0.52	0.49	0.3
Short Term Investments	0.85	0.55	0.32	-0.8	0.93	0.85	0.92	0.84	-0.01	0.43	0.08		0.93	0.25	-0.32	0.07	0.6	0.83	0.83	-0.45	-0.37	-0.33	0.07	0.81	0.83	0.83
Long Term Debt	0.82	0.46	0.42	-0.73	0.97	0.83	0.98	0.85	0.06	0.41	-0.07	0.93		0.31	-0.23	-0.01	0.55	0.82	0.78	-0.49	-0.23	-0.22	-0.08	0.8	0.82	0.8
Current Deferred Revenue	0.24	0.02	0.14	-0.23	0.36	0.24	0.28	0.32	-0.03	0.17	-0.06	0.25	0.31		-0.15	-0.12	0.25	0.21	0.23	-0.22	-0.18	-0.27	-0.1	0.15	0.17	0.24
Intangible Assets	-0.34	-0.31	0.12	0.39	-0.36	-0.33	-0.18	-0.42	0.87	-0.16	-0.1	-0.32	-0.23	-0.15		-0.23	-0.76	-0.4	-0.39	-0.34	0.81	-0.07	-0.1	-0.24	-0.24	-0.3
Net Tangible Assets	0.54	0.85	-0.89	-0.33	0.11	0.52	-0.06	0.31	-0.07	0.6	0.88	0.07	-0.01	-0.12	-0.23		0.19	0.04	0.44	-0.19	-0.3	0.24	0.86	0.56	0.52	0.38
Good Will	0.59	0.44	0.04	-0.52	0.66	0.58	0.52	0.65	-0.67	0.34	0.06	0.6	0.55	0.25	-0.76	0.19		0.6	0.58	0.21	-0.78	-0.04	0.07	0.5	0.51	0.53
Long Term Debt Total	0.69	0.37	0.34	-0.88	0.84	0.68	0.73	0.87	-0.07	0.58	-0.17	0.83	0.82	0.21	-0.4	0.04	0.6		0.86	-0.41	-0.49	0.08	-0.19	0.61	0.62	0.82
Capital Surpluse	0.9	0.73	-0.09	-0.97	0.81	0.89	0.67	0.94	-0.01	0.77	0.33	0.83	0.78	0.23	-0.39	0.44	0.58	0.86		-0.53	-0.48	-0.07	0.3	0.85	0.84	0.96
Deferred Long Term Liab	-0.5	-0.37	-0.05	0.53	-0.42	-0.49	-0.43	-0.37	-0.67	-0.33	-0.21	-0.45	-0.49	-0.22	-0.34	-0.19	0.21	-0.41	-0.53		-0.32	-0.04	-0.16	-0.54	-0.53	-0.64
Treasury Stock	-0.39	-0.38	0.18	0.48	-0.41	-0.38	-0.18	-0.51	0.7	-0.4	-0.13	-0.37	-0.23	-0.18	0.81	-0.3	-0.78	-0.49	-0.48	-0.32		-0.11	-0.14	-0.27	-0.26	-0.36
Long Term Investments	-0.15	-0.02	-0.2	0.06	-0.15	-0.18	-0.31	-0.15	-0.11	-0.01	-0.15	-0.33	-0.22	-0.27	-0.07	0.24	-0.04	0.08	-0.07	-0.04	-0.11		-0.16	-0.17	-0.21	-0.08
Short Long Term Debt	0.45	0.78	-0.85	-0.19	0.0	0.46	-0.07	0.15	0.02	0.39	1.0	0.07	-0.08	-0.1	-0.1	0.86	0.07	-0.19	0.3	-0.16	-0.14	-0.16		0.5	0.47	0.28
Net Invested Capital	0.98	0.89	-0.18	-0.73	0.82	0.99	0.78	0.8	0.07	0.63	0.52	0.81	0.8	0.15	-0.24	0.56	0.5	0.61	0.85	-0.54	-0.27	-0.17	0.5		1.0	0.85
Net Working Capital	0.98	0.87	-0.13	-0.73	0.84	0.99	0.81	0.81	0.07	0.6	0.49	0.83	0.82	0.17	-0.24	0.52	0.51	0.62	0.84	-0.53	-0.26	-0.21	0.47	1.0		0.85
Capital Stock	0.89	0.7	-0.02	-0.95	0.8	0.88	0.71	0.88	0.1	0.68	0.3	0.83	0.8	0.24	-0.3	0.38	0.53	0.82	0.96	-0.64	-0.36	-0.08	0.28	0.85	0.85

Click cells to compare fundamentals

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	6.1 M	6.4 M
Net Interest Income	-21.6 M	-20.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

TGTX Interest Income from 2010 to 2026

Latest TG Therapeutics' Interest Income Growth Pattern

TGTX Interest Income Regression Statistics

TGTX Interest Income History

Other Fundumenentals of TG Therapeutics

TG Therapeutics Interest Income component correlations

About TG Therapeutics Financial Statements

Also Currently Popular

Additional Tools for TGTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY